Tumor necrosis factor-alpha (TNF-α) antagonists’ therapy are expensive and has a non-responsive rate between 30% to 40% in rheumatoid arthritis patients. Genetic variation plays a vital role in the responsiveness to this type of therapy.The aim of this study is to investigate if the presence of genetic polymorphism in the TNF-α gene promoter region at locations -376 G/A (rs1800750), -806 C/T (rs4248158), and -1031 T/C (rs1799964) affects rheumatoid arthritis patient's tendency to be a non-responder to etanercept.

Eighty RA patients on etanercept (ETN) for at least six months were recruited from the Rheumatology Unit at Baghdad Teaching Hospital. Based on The European League Against Rheumatism response (EULAR) criteria, patient

Rheumatoid arthritis is a chronic, progressive, inflammatory autoimmune disease of unidentified etiology, associated with articular, extra-articular and systemic manifestation that require long-standing treatment. Taking patient’s beliefs about the prescribed medication in consideration had been shown to be an essential factor that affects adherence of the patient in whom having positive beliefs is an essential for better adherence. The purpose of the current study was to measure beliefs about medicines among a sample of Iraqi patients with Rheumatoid arthritis and to determine possible association between this belief and some patient-certain factors. This study is a cross-sectional study carried out on 250 already diagnosed rheumatoid

Background: Tumor necrosis factor-alpha (TNF-α) and interleukins play important roles in the pathogenesis of rheumatoid arthritis (RA). Genetic research has been employed to find many of the missing connections between genetic risk variations and causal genetic components. Objective: The goal of this study is to look at the genetic variations of TNF-α and interleukins in Iraqi RA patients and see how they relate to disease severity or response to biological therapy. Method: Using specific keywords, the authors conducted a systematic and comprehensive search to identify relevant Iraqi studies examining the genetic variations of TNF-α and interleukins in Iraqi RA patients and how they relate to disease severity or response to biolo

Background: Since the introduction of tumour necrosis factor-alpha (TNF-α) inhibitors including etanercept, their efficacy and safety in treatment of rheumatoid arthritis (RA) have been studied in many randomized controlled clinical trials. However, data regarding predictors of clinical response to anti-TNF therapy are still sparse.
Objective: To assess the predictors of response to etanercept in treatment of Iraqi patients with active RA.
Methods: An open label single group prospective study was conducted over 15 months on 190 Iraqi patients with RA. All the included patients were given etanercept at a dose of 50 mg by subcutaneous injection on
a weeklybases. Each patient was followed at regular intervals of bas

Background:Ankylosing spondylitis (AS) is a progressive, chronic inflammatory illness with an unclear etiology that explicitly targets the vertebral column, peripheral joints, and extraarticular tissues. The purpose of this research was to investigate if the existence of single nucleotide polymorphisms (SNPs) in the promoter region of the tumor necrosis factor-alpha (TNF-α) gene at positions -1031T/C (rs199964), -857C/T (rs1799724) and -806C/T (rs4248158) in a sample of Iraqi AS patients could influence the patients' outcomes with etanercept.

Methods:Sixty patients with established AS receiving only etanercept were selected to enroll in this study, with a mean age of 40.75±8.6

Folate metabolism is fundamental and essential for DNA structure synthesis and repair. Change in genes that participate in folate metabolism can be linked with different types of malignant tumor, Therefore, this study was conducted to find out the association between methylenetetrahydrofolatereductaseMTHFR gene polymorphisms and risk of breast cancer in a sample of Iraqi patients. One Single Nucleotide Polymorphism ( SNP) including MTHFR C677T was calculated using a tetra primer ARMS PCR experiment assay. The results explained that (MTHFR C677T) consists of three genotype (CC, CT, TT), The CC genotype was the most frequent in patients and control group ( 40.00%) and(60.00%) ,respectively, while the lowest frequency was for TT genotype(26

This study was conducted to evaluate the prevalence rate of
toxoplasmosis among 294 rheumatoid arthritis (RA) patients treated with
methotrexate (MTX), 50 RA patients without treatment and 50 samples as
healthy control. Blood samples were collected and the presence of T.gondii
IgG and IgM antibodies was determined by using Enzyme linked
immunosorbent assay (ELISA). Tumor necrosis factor alpha (TNF-α) was
also estimated in serum of all subjects by using ELISA method too. The
seroprevalence of toxoplasmosis IgM and IgG in RA+MTX was
60(20.408%), and 98(33.33%), in RA patients 4(8%), and 18(36%) while,
it was 2(24%), 6(12%) in healthy group. Tumor necrosis factor alpha
(TNF-α) was also estimated in serum of a

Background:

Background: The human CD19 (Cluster Differentiation) antigen is a 95 kd transmembrane glycoprotein belonging to the immunoglobulin superfamily. CD19 gene located on the short arm of chromosome 16p11.2 (P: petit). CD19 is a member of the Ig immunoglobulin superfamily expressed on the surface of B lymphocytes, and may play a pivotal role in B-cell differentiation and activation. Research suggests that mutations in a gene CD19 leads to a lack of expression of CD19 membrane and result in an antibody deficiency syndrome.
Objective: The aim of this work is to study the mutations in Exon 2 CD19gene in leukemia patients in Baghdad/Iraq.
Patients and Methods: This cross sectional study was performed in the National